Endothelin-1 (ET-1) has nociceptive effects in the tumor microenvironment and it is highly secreted in OSCC and targeting ET-1 in pre-clinical models has shown to have anti-nociceptive effects (18-20). Here, EDN1 is linked to neoplasm.